tumor necrosis factor-alpha potentiates the cytotoxicity of amiodarone in hepa1c1c7 cells: roles of...
TRANSCRIPT
Tumor necrosis factor-alpha potentiates the cytotoxicity of amiodarone in Hepa1c1c7 cells: roles of caspase activation and oxidative stress
Supplementary Figures
Jingtao Lu*†, Kazuhisa Miyakawa‡†, Robert A. Roth§† and Patricia E. Ganey§†,1. *Department of Biochemistry and Molecular Biology, †Center for Integrative Toxicology, ‡Department of Pathobiology and Diagnostic Investigation, §Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824, USA 1 To whom correspondence should be addressed at Department of Pharmacology and Toxicology, Michigan State University, 214 Food Safety and Toxicology Building, East Lansing, MI 48824. Fax: (517) 432-2310. E-mail [email protected].
Sal LPS
AL
T (
U/L
)
0
200
400
600
800
Veh AMD
Supplementary Figure 1. AMD/LPS-interaction caused hepatotoxicity in miceMice were treated with LPS (2×106 EU/kg, ip) or saline and 2h later with AMD (300 mg/kg, ip) or veh. Plasma ALT activity was measured at 24h after LPS. Two-way ANOVA was applied. #, significantly different from respective groups not given LPS; * significantly different from respective group not given AMD. Significant interaction were observed between AMD and LPS p< 0.05, n=3-6.
*#
AMD (uM)
0 40 60 100 125
LD
H (
% r
ele
as
e)
0
20
40
60
SalTNF
Supplementary Figure 2. TNF potentiation of AMD cytotoxicity in HepG2 cellsHepG2 cells were treated with AMD (40uM to 125uM) or saline and TNF (1 ug/ml) or saline. After 24h incubation, the release of LDH was determined as described in Materials and Methods. n=2.
Supplementary Figure 3. Activity of caspase 8 after AMD and/or TNF treatment Hepa1c1c7 cells were treated with 35μM AMD and/or 3ng/ml TNF for 1h, 12h, 24h or 48h, and activity of caspase 8 was measured as described in Materials and Methods. Results were presented as fold changes from Sal/Sal group. n=3-5. No significant differences were observed.
Time (h)
1 12 24 48
Ca
sp
as
e8
ac
tiv
ity
(fo
ld c
ha
ng
e f
rom
Sa
l/S
al)
0
1
2
3
Sal/SalSal/TNFAMD/SalAMD/TNF